Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters

(Kron) – Gilead Sciences announced on Wednesday that it was lengthening a new pharmaceutical and manufacturing center at its city headquarters. Development is part of the US innovation of $ 32 billion until 2030, according to a press statement issued by the Biotropic Company.

“This new facility is part of our vision to provide treatments from the next generation and the foundation stone stone for Gilead “We have many ongoing construction projects, all of which will generate thousands of American jobs and help push American leadership in creating global vital drugs.”

It is expected that the facilities consisting of five floors and 180,000 square feet will be generated more than $ 43 billion in the economic value and the establishment of more than 3,000 jobs, directly and indirectly, according to the California Governor’s Office, Gavin News

Gillyid said the facility will be a center for innovation and cooperation through technical and manufacturing teams.

“NTDC is designed with a flexible experimental laboratory space and advanced digital infrastructure, NTDC will accelerate technology transfer and support biology from the next generation via the Gilead pipeline,” says the press statement. “It will contain digital systems, independent robots and digital monitoring in an actual time, making it one of the most centers that support artificial intelligence in the biological drug industry.”

“California is proud to be home to Gilead science and its continuous investment in innovation and jobs here in the city of Foster,” said Lieutenant California Ellenie Konalakis. “This new technical development center is more than just a milestone for Gilead; it is a victory for all those who will benefit from its penetrations.”

Gilead is currently developing two other sites, a research building “designed to accelerate the scientific discovery” already under construction; And a biological manufacturing facility to expand production capabilities locally.

Leave a Comment